oral fluoropyrimidines
Recently Published Documents


TOTAL DOCUMENTS

53
(FIVE YEARS 3)

H-INDEX

14
(FIVE YEARS 1)

2021 ◽  
Vol 13 ◽  
pp. 175883592110090
Author(s):  
Pilar García-Alfonso ◽  
Andrés Jesús Muñoz Martín ◽  
Laura Ortega Morán ◽  
Javier Soto Alsar ◽  
Gabriela Torres Pérez-Solero ◽  
...  

Colorectal cancer (CRC) is one of the most common forms of cancer, with an estimated 1.36 million new cases and almost 700,000 deaths annually. Approximately 21% of patients with CRC have metastatic disease at diagnosis. The objective of this article is to review the literature on the efficacy and safety of oral drugs available for the treatment of metastatic colorectal cancer (mCRC). Several such drugs have been developed, and fluoropyrimidines are the backbone of chemotherapy in this indication. They exert their antitumour activity by disrupting the synthesis and function of DNA and RNA. Oral fluoropyrimidines include prodrugs capecitabine, tegafur, eniluracil/5-fluorouracil, tegafur/uracil, tegafur/gimeracil/oteracil and trifluridine/tipiracil (FTD/TPI). Oral drugs offer several advantages over injectable formulations, including convenience, flexibility, avoidance of injection-related adverse events (AEs) and, in some circumstances, lower costs. However, oral drugs may not be suitable for patients with gastrointestinal obstruction or malabsorption, they may result in reduced treatment adherence and should not be co-administered with drugs that interfere with absorption or hepatic metabolism. Oral fluoropyrimidines such as capecitabine, as monotherapy or in combination with oxaliplatin, irinotecan or bevacizumab, are as effective as intravenous 5-fluorouracil (5-FU) in first-line treatment of mCRC. Other oral fluoropyrimidines, such as FTD/TPI, are effective in patients with mCRC who are refractory, intolerant or ineligible for 5-FU. In addition, oral fluoropyrimidines are used in adjuvant treatment of mCRC. Regorafenib is an oral multikinase inhibitor used in patients in whom several previous lines of therapy have failed. Frequent AEs associated with oral drugs used in the treatment of CRC include hand-foot syndrome and gastrointestinal and haematological toxicities.


2016 ◽  
Vol 36 (10) ◽  
pp. 5325-5332 ◽  
Author(s):  
KEIJI KODA ◽  
HIDEAKI MIYAUCHI ◽  
CHIHIRO KOSUGI ◽  
TAKASHI TAKASHI ◽  
TAKASHI TAKASHI ◽  
...  

2016 ◽  
Vol 17 (5) ◽  
pp. 433-440.e1
Author(s):  
Shinsuke Sasada ◽  
Yoshihiro Miyata ◽  
Takahiro Mimae ◽  
Yasuhiro Tsutani ◽  
Takeshi Mimura ◽  
...  

2013 ◽  
Vol 31 (20) ◽  
pp. 2600-2606 ◽  
Author(s):  
Nadine J. McCleary ◽  
Jeffrey A. Meyerhardt ◽  
Erin Green ◽  
Greg Yothers ◽  
Aimery de Gramont ◽  
...  

Purpose Prior studies have suggested that patients with stage II/III colon cancer receive similar benefit from intravenous (IV) fluoropyrimidine adjuvant therapy regardless of age. Combination regimens and oral fluorouracil (FU) therapy are now standard. We examined the impact of age on colon cancer recurrence and mortality after adjuvant therapy with these newer options. Patients and Methods We analyzed 11,953 patients age < 70 and 2,575 age ≥ 70 years from seven adjuvant therapy trials comparing IV FU with oral fluoropyrimidines (capecitabine, uracil, or tegafur) or combinations of fluoropyrimidines with oxaliplatin or irinotecan in stage II/III colon cancer. End points were disease-free survival (DFS), overall survival (OS), and time to recurrence (TTR). Results In three studies comparing oxaliplatin-based chemotherapy with IV FU, statistically significant interactions were not observed between treatment arm and age (P interaction = .09 for DFS, .05 for OS, and .36 for TTR), although the stratified point estimates suggested limited benefit from the addition of oxaliplatin in elderly patients (DFS hazard ratio [HR], 0.94; 95% CI, 0.78 to 1.13; OS HR, 1.04; 95% CI, 0.85 to 1.27). No significant interactions by age were detected with oral fluoropyrimidine therapy compared with IV FU; noninferiority was supported in both age populations. Conclusion Patients age ≥ 70 years seemed to experience reduced benefit from adding oxaliplatin to fluoropyrimidines in the adjuvant setting, although statistically, there was not a significant effect modification by age, whereas oral fluoropyrimidines retained their efficacy.


2012 ◽  
Vol 23 ◽  
pp. iv52
Author(s):  
Manal Abdel Wahab ◽  
Mohammed Shaker ◽  
Sherif Abdel Wahab ◽  
Mohammed Elbassiouny ◽  
Mahmoud Ellithy ◽  
...  

2012 ◽  
Vol 103 ◽  
pp. S414
Author(s):  
C. Fuentes Sanchez ◽  
R. Hernández González Ruth ◽  
J.J. Martín Ortega ◽  
J.M. Ponce Ortega ◽  
R. Cabrera Diaz-Saavedra ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document